# To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

> **NCT06500689** · PHASE3 · COMPLETED · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 366 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Allisartan Isoproxil/Sustained-Release Indapamide
- **DRUG:** Allisartan Isoproxil

## Key facts

- **NCT ID:** NCT06500689
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-30
- **Primary completion:** 2023-11-27
- **Final completion:** 2024-05-24
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06500689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06500689, "To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06500689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*